AnaptysBio Plans Q2 Royalty Spin; Jemperli Uptake and Q4 ANB033 Celiac Data
AnaptysBio will spin off its royalty interests from partnered programs in Q2 to bolster liquidity and support pipeline advancement. Jemperli continued to see commercial uptake in cancer indications while initial efficacy and safety data for ANB033 in celiac disease are expected in Q4.
1. Q2 Royalty Spin Initiative
AnaptysBio has outlined a plan to spin off its royalty interests in partnered immunology and oncology assets during Q2, aiming to unlock upfront capital and generate ongoing royalties that can be reinvested into early-stage development programs.
2. Jemperli Commercial Growth
The company highlighted continued expansion of Jemperli in oncology, noting broader adoption across endometrial cancer treatment protocols and steady growth in prescription volumes compared with prior quarters.
3. ANB033 Celiac Trial Timeline
AnaptysBio expects to release initial safety and efficacy results for ANB033 in celiac disease during Q4, with data readouts designed to assess mucosal healing and symptom improvement to inform potential partnership or licensing discussions.